Cargando…

Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma

Detalles Bibliográficos
Autores principales:	Ma, Dongshen, Zhang, Qin, Duan, Qianqian, Tan, Yuan, Sun, Tingting, Qi, Chuang, Qin, Yong, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004013/ https://www.ncbi.nlm.nih.gov/pubmed/35410220 http://dx.doi.org/10.1186/s12967-022-03324-8

Ejemplares similares

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
por: Li, Hongxia, et al.
Publicado: (2022)

Predominance of triple wild-type and IGF2R mutations in mucosal melanomas
por: Iida, Yuuki, et al.
Publicado: (2018)

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
por: Dong, Yiting, et al.
Publicado: (2022)

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets
por: Zhang, Yinqi, et al.
Publicado: (2021)

Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer
por: Feng, Fen, et al.
Publicado: (2022)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)

Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations
por: Kawashima-Sonoyama, Yuki, et al.
Publicado: (2022)

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
por: Wang, Zemin, et al.
Publicado: (2022)

Advances in targeted therapy and immunotherapy for melanoma (Review)
por: Qin, Ziyao, et al.
Publicado: (2023)

A case of vaginal melanoma with multi-line immunotherapy and reflections
por: Deng, Xia
Publicado: (2023)

Role of gut microbiome on immunotherapy efficacy in melanoma
por: Bibbò, Stefano, et al.
Publicado: (2021)

Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
por: Dextras, Christopher, et al.
Publicado: (2020)

Targeted Therapy and Immunotherapy for Melanoma in Japan
por: Namikawa, Kenjiro, et al.
Publicado: (2019)

Immunotherapy for Non-melanoma Skin Cancer
por: Shalhout, Sophia Z., et al.
Publicado: (2021)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

LAG3 and its emerging role in cancer immunotherapy
por: Wang, Miao, et al.
Publicado: (2021)

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
por: Ramcharan, Roger, et al.
Publicado: (2015)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Recurrent somatic mutations as predictors of immunotherapy response
por: Gajic, Zoran Z., et al.
Publicado: (2022)

IGF1R immunohistochemistry in Ewing’s sarcoma as predictor of response to targeted therapy
por: Gonzalez, Elizabeth, et al.
Publicado: (2020)

Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022
por: Tan, Yao, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
por: Li, Ying, et al.
Publicado: (2020)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System
por: Xin, Haoran, et al.
Publicado: (2018)

A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma
por: Yuan, Tze-An, et al.
Publicado: (2020)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis
por: Zeng, Furong, et al.
Publicado: (2023)

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
por: Neuzillet, Yann, et al.
Publicado: (2017)

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
por: Wang, Qinghua, et al.
Publicado: (2021)

Immunotherapy of melanoma
por: Haanen, John B.A.G.
Publicado: (2013)

Melanoma immunotherapy
por: Garg, Abhishek D., et al.
Publicado: (2015)

Immunotherapy of melanoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
por: Lorenz, Anna, et al.
Publicado: (2022)

Using T‐cell repertoire profiles as predictor in a primary mucosal melanoma
por: Chang, Che‐Mai, et al.
Publicado: (2020)

lncRNA IGF2‐AS regulates miR‐500a‐3p/PPP4R1/p‐VEGFR2 signalling pathway to promote thyroid carcinoma progression and tubulogenesis
por: Xiang, Yuan, et al.
Publicado: (2023)

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
por: Hargadon, Kristian M.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l2aleq772daslfq2fbptv86g3f